Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses outcomes of chronic lymphocytic leukemia (CLL) patients following treatment with a covalent BTK and BCL2 inhibitor. Dr Eyre comments on how the treatment paradigm in CLL is changing with an increase in available agents, and further highlights the importance of focusing on patients who progress following treatment with these two agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.